These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33724860)

  • 1. Thermal treatment decreases resistance to osimertinib in non-small cell lung cancer through the EGFR/PI3K/AKT pathway.
    Wang J; Ling X; Zhou M; Ding G; Peng B; Wan J
    Neoplasma; 2021 May; 68(3):535-545. PubMed ID: 33724860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line.
    Tang ZH; Jiang XM; Guo X; Fong CM; Chen X; Lu JJ
    Oncotarget; 2016 Dec; 7(49):81598-81610. PubMed ID: 27835594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.
    Yan D; Huelse JM; Kireev D; Tan Z; Chen L; Goyal S; Wang X; Frye SV; Behera M; Schneider F; Ramalingam SS; Owonikoko T; Earp HS; DeRyckere D; Graham DK
    J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35708914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.
    Liu K; Chen X; Wu L; Chen S; Fang N; Cai L; Jia J
    BMC Pulm Med; 2021 May; 21(1):163. PubMed ID: 33992097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased Expression of IRE1α Associates with the Resistant Mechanism of Osimertinib (AZD9291)-resistant non-small Cell Lung Cancer HCC827/OSIR Cells.
    Tang ZH; Su MX; Guo X; Jiang XM; Jia L; Chen X; Lu JJ
    Anticancer Agents Med Chem; 2018; 18(4):550-555. PubMed ID: 28730963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer.
    Chen W; Yu D; Sun SY; Li F
    Acta Biomater; 2021 Jul; 129():258-268. PubMed ID: 34048974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
    Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
    Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osimertinib Induces the Opposite Effect of Proliferation and Migration in the Drug Resistance of EGFR-T790M Non-small Cell Lung Cancer Cells.
    Wang RH; Chang CJ; Chen CH; Liu KK; Chao JI
    Anticancer Agents Med Chem; 2023; 23(11):1309-1319. PubMed ID: 36815658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer.
    Wu S; Luo M; To KKW; Zhang J; Su C; Zhang H; An S; Wang F; Chen D; Fu L
    Mol Cancer; 2021 Jan; 20(1):17. PubMed ID: 33461557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC.
    Haratake N; Ozawa H; Morimoto Y; Yamashita N; Daimon T; Bhattacharya A; Wang K; Nakashoji A; Isozaki H; Shimokawa M; Kikutake C; Suyama M; Hashinokuchi A; Takada K; Takenaka T; Yoshizumi T; Mitsudomi T; Hata AN; Kufe D
    J Thorac Oncol; 2024 Mar; 19(3):434-450. PubMed ID: 37924972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of vitamin D on malignant behavior of non-small cell lung cancer cells.
    Songyang Y; Song T; Shi Z; Li W; Yang S; Li D
    Gene; 2021 Feb; 768():145309. PubMed ID: 33197518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance.
    Jiang XM; Xu YL; Yuan LW; Zhang LL; Huang MY; Ye ZH; Su MX; Chen XP; Zhu H; Ye RD; Lu JJ
    Acta Pharmacol Sin; 2021 Mar; 42(3):451-459. PubMed ID: 32678313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro.
    Wang J; Wei H; Zhao B; Li M; Lv W; Lv L; Song B; Lv S
    J Mol Histol; 2014 Dec; 45(6):641-52. PubMed ID: 25008024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
    Qu Y; Wu X; Yin Y; Yang Y; Ma D; Li H
    J Exp Clin Cancer Res; 2014 Jun; 33(1):52. PubMed ID: 24939055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disclosing Potential Therapeutic Targets Associated With Osimertinib Resistance in the Non-small Cell Lung Cancer Cell Line H1975.
    Tong X; Zhang R; Sun R; Yang W; Sun J; Chen J; Li F
    Anticancer Res; 2023 Dec; 43(12):5459-5474. PubMed ID: 38030186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of almonertinib on the proliferation, invasion, and migration in non-small cell lung cancer cells.
    Zhang Y; Zhang Y; Niu W; Ge X; Li X; Fan F; Li S; Liu H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Oct; 46(10):1045-1053. PubMed ID: 34911833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperthermia induced HIF-1a expression of lung cancer through AKT and ERK signaling pathways.
    Wan J; Wu W
    J Exp Clin Cancer Res; 2016 Jul; 35(1):119. PubMed ID: 27456341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Ephedra Herb extract on the expression of EGFR-activating mutations and c-Met in non-small-cell lung cancer cell line, H1975, and its combined effects with osimertinib.
    Mori E; Hyuga S; Hanawa T; Naoki K; Odaguchi H
    J Nat Med; 2023 Jun; 77(3):523-534. PubMed ID: 37043119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incomplete radiofrequency ablation accelerates proliferation and angiogenesis of residual lung carcinomas via HSP70/HIF-1α.
    Wan J; Wu W; Huang Y; Ge W; Liu S
    Oncol Rep; 2016 Aug; 36(2):659-68. PubMed ID: 27278081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies.
    Tang ZH; Lu JJ
    Cancer Lett; 2018 Apr; 420():242-246. PubMed ID: 29425688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.